UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of Directors
On February 23, 2024, the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), upon the recommendation of the nominating and corporate governance committee of the Board, appointed Patrick Kennedy to the Board, effective as of March 1, 2024, as a Class I director for a term expiring at the annual general meeting of shareholders to be held in 2024. Mr. Kennedy was also appointed to serve as a member of the Audit Committee of the Board. There were no arrangements or understandings between Mr. Kennedy and any other persons pursuant to which Mr. Kennedy was selected as a director.
Mr. Kennedy will receive cash and equity compensation for his service on the Board in accordance with the Company’s standard compensatory arrangements for non-employee directors described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2023.
In connection with his election to the Board, the Company and Mr. Kennedy entered into the Company’s standard indemnification agreement that requires the Company, under the circumstances and to the extent provided for therein, to indemnify Mr. Kennedy to the fullest extent permitted by applicable law against certain expenses and other amounts incurred by either Mr. Kennedy as a result of Mr. Kennedy being made a party to certain actions, suits, proceedings and other actions by reason of the fact that Mr. Kennedy is or was a director, officer, employee, consultant, agent or fiduciary of the Company or any of its subsidiaries or other affiliated enterprises.
Resignation of Directors
On February 23, 2024, Peter Gray notified the Board that he will not stand for re-election to the Board, when his term expires, at the 2024 Annual Meeting. Mr. Gray’s decision was not the result of any dispute or disagreement with the Company or the Company’s Board on any matter relating to the operations, policies or practices of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | ||
| By: | /s/ Neena Patil | |
| Name: | Neena Patil | |
| Title: | Executive Vice President and Chief Legal Officer | |
Date: February 27, 2024
Document and Entity Information |
Feb. 23, 2024 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | Jazz Pharmaceuticals plc |
| Amendment Flag | false |
| Entity Central Index Key | 0001232524 |
| Document Type | 8-K |
| Document Period End Date | Feb. 23, 2024 |
| Entity Incorporation State Country Code | L2 |
| Entity File Number | 001-33500 |
| Entity Tax Identification Number | 98-1032470 |
| Entity Address, Address Line One | Fifth Floor |
| Entity Address, Address Line Two | Waterloo Exchange |
| Entity Address, Address Line Three | Waterloo Road |
| Entity Address, City or Town | Dublin 4 |
| Entity Address, Country | IE |
| Entity Address, Postal Zip Code | D04 E5W7 |
| City Area Code | 011-353-1 |
| Local Phone Number | 634-7800 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Ordinary shares, nominal value $0.0001 per share |
| Trading Symbol | JAZZ |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |